EMA Authorised: Orserdu (elacestrant) — Stemline Therapeutics B.V.

View source ↗

Summary

The European Medicines Agency authorised Orserdu (elacestrant) for ER-positive, HER2-negative advanced or metastatic breast cancer; decision date 25 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Orserdu (Elacestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Stemline Therapeutics B.V.. Decision date: 25/03/2026